Patrick J. Heron - May 29, 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
Director
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Stock symbol
MIRM
Transactions as of
May 29, 2025
Transactions value $
$0
Form type
4
Date filed
6/2/2025, 07:39 PM
Previous filing
May 23, 2025
Next filing
Jun 6, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Heron Patrick J Director C/O MIRUM PHARMACEUTICALS, INC., 989 E. HILLSDALE BLVD., SUITE 300, FOSTER CITY /s/ Judit Ryvkin, Attorney-in-Fact 2025-06-02 0001365617

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise +5.7K 5.7K May 29, 2025 Direct F1
holding MIRM Common Stock 3.57M May 29, 2025 By Frazier Life Sciences IX, L.P. F2
holding MIRM Common Stock 169K May 29, 2025 By Frazier Life Sciences X, L.P. F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Restricted Stock Units Options Exercise $0 -5.7K -100% $0.00 0 May 29, 2025 Common Stock 5.7K Direct F1, F4
transaction MIRM Stock Option (right to buy) Award $0 +6.27K $0.00 6.27K May 29, 2025 Common Stock 6.27K $44.00 Direct F5
transaction MIRM Deferred Stock Units Award $0 +3.98K $0.00 3.98K May 29, 2025 Common Stock 3.98K Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (or its cash equivalent, at the discretion of the Issuer).
F2 The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3 The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F4 The restricted stock unit vests on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting.
F5 The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting.
F6 Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.